1. Is Alembic Pharmaceuticals Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Alembic Pharmaceuticals Ltd is a good quality company.
2. Is Alembic Pharmaceuticals Ltd undervalued or overvalued?
The key valuation ratios of Alembic Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
3. Is Alembic Pharmaceuticals Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Alembic Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||24.7%||33.1%||29.1%||50.3%||22.2%||15.9%||17.2%||19.8%||20.9%||8.7%||-|
|Value Creation Index ⓘ||0.8||1.5||1.2||2.7||0.6||0.2||0.3||0.5||0.6||-0.4||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||22.6%||10.4%||54%||-1%||-0.1%||25.7%||17.1%||17.1%||-1.6%||-|
|Adj EPS ⓘ||8.5||12.6||14.8||38||21.6||20.7||30.2||45.2||55.3||24.8||16|
|YoY Gr. Rt. %||-||47.3%||17.9%||156.6%||-43.1%||-4.3%||46.2%||49.6%||22.6%||-55.2%||-|
|BVPS (₹) ⓘ||26.7||35.8||46.9||84.7||100.9||117.8||144.2||170.8||257.8||266.5||263.5|
|Adj Net Profit ⓘ||161||237||279||715||407||389||569||851||1,088||487||315|
|Cash Flow from Ops. ⓘ||265||240||172||948||329||312||812||449||1,463||552||-|
|Debt/CF from Ops. ⓘ||0.7||0.5||1.5||0.1||0.3||2.3||1.4||3.9||0.3||1.1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||12.6%||2.8%||-6.4%||-55.2%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||35.8||40.2||35.7||57.7||23.3||18.9||23||28.7||26.3||9.5||6.1|
|Op. Profit Mgn % ⓘ||16.4||19.4||19.2||31.8||19.8||19.7||21.8||26.4||27.4||16.5||13.1|
|Net Profit Mgn % ⓘ||10.6||12.7||13.6||22.6||13.1||12.7||14.7||17.9||19.6||9.1||6|
|Debt to Equity ⓘ||0.4||0.2||0.3||0.1||0.1||0.3||0.4||0.5||0.1||0.1||-|
|Working Cap Days ⓘ||175||163||168||133||159||194||182||178||174||192||0|
|Cash Conv. Cycle ⓘ||45||39||47||16||26||32||38||69||70||88||0|
Sales growth is growing at healthy rate in last 3 years 10.48%
Return on Equity has declined versus last 3 years average to 6.10%
Net Profit has been subdued in last 3 years -6.37%
Sales growth is not so good in last 4 quarters at -2.20%
|TTM EPS (₹)||34.3||16|
|TTM Sales (₹ Cr.)||4,887||5,242|
|BVPS (₹.) ⓘ||272.8||263.5|
|Reserves (₹ Cr.) ⓘ||5,324||5,140|
|From the Market|
|52 Week Low / High (₹)||600.00 / 863.10|
|All Time Low / High (₹)||34.00 / 1150.00|
|Market Cap (₹ Cr.)||11,970|
|Equity (₹ Cr.)||39.3|
|Face Value (₹)||2|
|Industry PE ⓘ||37.9|
The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.
With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.
Business area of the company
The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.
Awards and recognition